Maurie Markman

Maurie Markman is a prominent medical oncologist with a distinguished career spanning leading cancer institutions including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and ultimately Cancer Treatment Centers of America. He has been a major contributor to the understanding and management of ovarian cancer, particularly championing the role of intraperitoneal (IP) chemotherapy in improving survival for optimally debulked patients. His work helped establish IP cisplatin and paclitaxel as a standard approach for select ovarian cancer patients following GOG 172. Markman has also conducted important clinical and translational research on carboplatin hypersensitivity reactions, characterizing their incidence, risk factors, and management strategies. His studies have enabled safer re-treatment of patients with platinum-sensitive recurrent ovarian cancer who develop infusion hypersensitivity, preserving access to effective therapy. He has authored hundreds of peer-reviewed publications and multiple textbooks on clinical oncology. A prolific educator and communicator, Markman has been a leading voice in translating clinical trial data into practical management guidelines. He served as a principal investigator on numerous cooperative group studies and has contributed extensively to the evidence base for both first-line and recurrent ovarian cancer treatment.